地舒单抗效果怎么样？

It is approved for use in patients with giant cell tumor of bone that cannot be surgically removed or is likely to cause severe functional impairment due to its dual effects of inhibiting tumor growth and reducing bone destruction, as well as its good tolerability.

Regarding the drug mechanism of denosumab, Professor Niu said: Osteoblasts and osteoclasts generally maintain dynamic stability, but tumor cells destroy this stability and can over-secret RANKL to promote osteolysis. Desosumab inhibits osteolysis by binding to RANKL and eliminating its role in activating osteoclastoma activity.

Desosumab can generally be clinically effective within three months, has a low failure rate, and can well control the development of tumors. For some patients with poor results, the reasons for the failure are still being studied, but factors such as clinical diagnosis errors cannot be ruled out. In addition, Professor Niu reminded everyone that denosumab is contraindicated in patients with hypocalcemia. These patients need to correct their abnormal blood calcium before they can receive denosumab treatment.

It is a fully humanized immunoglobulin (Ig) G2 monoclonal antibody prepared using DNA recombinant technology. Its target is receptor activator of nuclear factor-κB ligand (RANKL). Recent studies have shown that the nuclear factor-κB receptor activator/nuclear factor-κB receptor activator ligand/osteoprotegerin (RANK/RANKL/OPG) system plays a key role in the maturation and activation of osteoclasts, maintains bone metabolic balance, and is also involved in the occurrence of SRE in malignant tumor bone metastases.

For more information about denosumab, please contact Medical Companion Travel for details.

Recommended related hot articles: /newsDetail/83721.html